尹富成｜南华大学｜学者主页

2026

Discover of a highly effective covalent inhibitor of CDK6 for triple-negative breast cancer treatment.

Jingting Zeng, Fucheng Yin, Yong-zeng Fan, Ke Zheng, Zi-Feng Zhang, Liu-Xue-Ying Liu, Renxin Jiang, Na Li, Fanglan Liu, Chunhua Xia, Cheng Wang

European journal of medicinal chemistry

DOI

2025

Cascade synthesis of miltirone derivatives via arylation, decarboxylation, and aromatization for their potential as antitumor agents.

Hui-Lian Huang, Fucheng Yin, Yong-Lei Zhang, Zhong-Wen Luo, Siyuan Wan, Liangliang Ma, Xiao-Bing Wang

Bioorganic chemistry (Print)

DOI

2025

Design and Synthesis of PARP/CDK6 Dual-Target Inhibitors Modulating of Wnt/β-Catenin Signaling Pathway for the Treatment of BRCA Wild-Type TNBC.

Yong-Lei Zhang, Fucheng Yin, Zhong-Wen Luo, Yiwei Zheng, Shun-Xin Guo, Sijie Wu, Yu-Han Jiang, Long Zheng, Liangliang Ma, Meiting Zou, Xiao-Bing Wang, Ling-Yi Kong

Journal of Medicinal Chemistry

DOI

2025

Correction to "Discovery of Dual CDK6/BRD4 Inhibitor Inducing Apoptosis and Increasing the Sensitivity of Ferroptosis in Triple-Negative Breast Cancer".

Yong-Lei Zhang, Long Zheng, Liangliang Ma, Fucheng Yin, Zhong-Wen Luo, Shang Li, Yu-Han Jiang, Lingyi Kong, Xiao-Bing Wang

Journal of Medicinal Chemistry

DOI

2024

Stereoselective Synthesis of β, γ-Fused Bicyclic γ-Ureasultams via an Intramolecular Mannich and aza-Michael Addition Cascade.

Fucheng Yin, Lailiang Qu, Yifan Chen, Zhong-Wen Luo, Lingyi Kong, Xiao-Bing Wang

Chemistry

DOI

2024

Regioselective Olefination and Arylation of Arene-Tethered Diols Using the Easily Foldable Directing Groups.

Fucheng Yin, Yifan Chen, Zhong-Wen Luo, Shang Li, Yong-Lei Zhang, Siyuan Wan, Xinxin Li, Lingyi Kong, Xiao-Bing Wang

Organic Letters

DOI

2024

Polypharmacological Drug Design Guided by Integrating Phenotypic and Restricted Fragment Docking Strategies.

Shang Li, Xinxin Li, Liangliang Ma, Zhong-Wen Luo, Fucheng Yin, Yong-Lei Zhang, Yifan Chen, Siyuan Wan, Han Zhou, Xiao-Bing Wang, Ling-Yi Kong

Journal of Medicinal Chemistry

DOI

2024

Discovery of Dual CDK6/BRD4 Inhibitor Inducing Apoptosis and Increasing the Sensitivity of Ferroptosis in Triple-Negative Breast Cancer.

Yong-Lei Zhang, Long Zheng, Liangliang Ma, Fucheng Yin, Zhong-Wen Luo, Shang Li, Yu-Han Jiang, Ling-Yi Kong, Xiao-Bing Wang

Journal of Medicinal Chemistry

DOI

2024

Progress in approved drugs from natural product resources.

Zhong-Wen Luo, Fucheng Yin, Xiao-bing Wang, Lingyi Kong

Chinese Journal of Natural Medicines

DOI

2024

Discovery of Covalent MLKL PROTAC Degraders via Optimization of a Theophylline Derivative Ligand for Treating Necroptosis.

Shang Li, Liangliang Ma, Xinxin Li, Yu-Han Jiang, Zhong-Wen Luo, Fucheng Yin, Yong-Lei Zhang, Yifan Chen, Siyuan Wan, Han Zhou, Ling-Yi Kong, Xiao-Bing Wang

Journal of Medicinal Chemistry

DOI

2024

Copper(II)/Rhodium(III)‐Catalyzed Three‐Component Sequential Annulation‐Olefination of 2‐Arylquinoxalines

Yifan Chen, Fucheng Yin, Zhong-Wen Luo, Shang Li, Yong-Lei Zhang, Xinxin Li, Siyuan Wan, Lingyi Kong, Xiao-Bing Wang

Annalen der Pharmacie

DOI

2024

Improving tumor sensitivity by the introduction of an ester chain to triaryl derivatives targeting PD-1/PD-L1.

Yong-Lei Zhang, Fucheng Yin, Zhong-Wen Luo, Shang Li, Xinxin Li, Siyuan Wan, Yifan Chen, Lingyi Kong, Xiao-Bing Wang

European journal of medicinal chemistry

DOI

2023

Two types of coumarins-specific enzymes complete the last missing steps in pyran- and furanocoumarins biosynthesis

Yu-Cheng Zhao, Yue-Dong He, Liangliang Han, Li-Bo Zhang, Yuan-Zheng Xia, Fucheng Yin, Xiao-Bing Wang, Deqing Zhao, Sheng Xu, Fei Qiao, Yibei Xiao, Lingyi Kong

Acta Pharmaceutica Sinica B

DOI

2023

Dual target PARP1/EZH2 inhibitors inducing excessive autophagy and producing synthetic lethality for triple-negative breast cancer therapy.

Xinxin Li, Cheng Wang, Shang Li, Fucheng Yin, Heng Luo, Yong-Lei Zhang, Zhong-Wen Luo, Yifan Chen, Siyuan Wan, Lingyi Kong, Xiao-Bing Wang

European journal of medicinal chemistry

DOI

2023

Discovery, Structure, and Mechanism of the (R, S)-Norcoclaurine Synthase for the Chiral Synthesis of Benzylisoquinoline Alkaloids

Li-Bo Zhang, Shi-Qing Zhang, Lijing Liao, Huanying Tang, Wen-Li Wang, Fucheng Yin, Liangliang Han, Ke-Jin Zhu, Yushi Liu, Dingqiao Xu, Xiao-Bing Wang, Minjian Qin, Yibei Xiao, X. Sheng, Yu-Cheng Zhao

ACS Catalysis

DOI

2023

Oxazole-4-carboxamide/butylated hydroxytoluene hybrids with GSK-3β inhibitory and neuroprotective activities against Alzheimer's disease.

Zhongwen Luo, Shun-Jie Li, Yong-Lei Zhang, Fucheng Yin, Heng Luo, Xinye Chen, N. Cui, Siyuan Wan, Xinxin Li, Lingyi Kong, Xiao-Bing Wang

European journal of medicinal chemistry

DOI

2023

Indirubin derivatives as bifunctional molecules inducing DNA damage and targeting PARP for the treatment of cancer.

Siyuan Wan, Xinye Chen, Fucheng Yin, Shang Li, Yong-Lei Zhang, Heng Luo, Zhong-Wen Luo, N. Cui, Yifan Chen, Xinxin Li, Lingyi Kong, Xiao-Bing Wang

European journal of medicinal chemistry

DOI

2023

Discovery of dual PARP and CDK6 inhibitors for triple-negative breast cancer with wild-type BRCA.

Cheng Wang, Heng Luo, Xinye Chen, Yong-Lei Zhang, Dehua Lu, Xingchen Liu, Fucheng Yin, Shun-Jie Li, Lingyi Kong, Xiao-Bing Wang

Bioorganic chemistry (Print)

DOI

2023

Discovery of Sibiriline derivatives as novel receptor-interacting protein kinase 1 inhibitors.

N. Cui, Shun-Jie Li, Yong-Lei Zhang, Fucheng Yin, Xinye Chen, Zhongwen Luo, Siyuan Wan, Xinxin Li, Lingyi Kong, Xiao-Bing Wang

European journal of medicinal chemistry

DOI

2023

Design, synthesis and mechanism studies of dual EZH2/BRD4 inhibitors for cancer therapy.

Xinye Chen, Cheng Wang, Dehua Lu, Heng Luo, Shun-Jie Li, Fucheng Yin, Zhongwen Luo, N. Cui, Lingyi Kong, Xiao-Bing Wang

Bioorganic & Medicinal Chemistry

DOI

2022

Discovery of precision targeting EZH2 degraders for triple-negative breast cancer.

Cheng Wang, Xinye Chen, Xingchen Liu, Dehua Lu, Shun-Jie Li, Lailiang Qu, Fucheng Yin, Heng Luo, Yong-Lei Zhang, Zhongwen Luo, N. Cui, Lingyi Kong, Xiao-Bing Wang

European journal of medicinal chemistry

DOI

2022

Histone Deacetylase and Enhancer of Zeste Homologue 2 Dual Inhibitors Presenting a Synergistic Effect for the Treatment of Hematological Malignancies.

Dehua Lu, Cheng Wang, Lailiang Qu, Fucheng Yin, Shun-Jie Li, Heng Luo, Yong-Lei Zhang, Xingchen Liu, Xinye Chen, Zhongwen Luo, N. Cui, Lingyi Kong, Xiao-Bing Wang

Journal of Medicinal Chemistry

DOI

2022

Harmine-based dual inhibitors targeting histone deacetylase (HDAC) and DNA as a promising strategy for cancer therapy.

Dehua Lu, Lailiang Qu, Cheng Wang, Heng Luo, Shun-Jie Li, Fucheng Yin, Xingchen Liu, Xinye Chen, Zhongwen Luo, N. Cui, Wan Peng, Limei Ji, Lingyi Kong, Xiao-Bing Wang

Bioorganic chemistry (Print)

DOI

2022

Aryl Halides as Halogenation Reagents in the Bromination and Iodination of Arene-Tethered Diols.

Fucheng Yin, Yifan Chen, Zhongwen Luo, Shun-Jie Li, Lingyi Kong, Xiao-Bing Wang

Organic Letters

DOI

2022

Rhodium(III)‐ Catalyzed Cleavage of C‐C Bond and C‐H Bond Cascaded by Michael Addition for the Conversion of α‐Hydroxy Ketones to Phthalides and Isocoumarins

Fucheng Yin, Wan Peng, Cheng Wang, Lailiang Qu, Xinye Chen, Lingyi Kong, Xiao-Bing Wang

Asian Journal of Organic Chemistry

DOI

2021

Rhodium(iii) catalyzed olefination and deuteration of tetrahydrocarbazole

Wan Peng, Qiaohong Liu, Fucheng Yin, Cunjian Shi, Limei Ji, Lailiang Qu, Cheng Wang, Heng Luo, Ling-Yi Kong, Xiaobing Wang

RSC Advances

DOI

2021

Parthenolide Derivatives as PKM2 Activators Showing Potential in Colorectal Cancer.

Xingchen Liu, Cheng Wang, Shang Li, Lailiang Qu, Fucheng Yin, Dehua Lu, Heng Luo, Xinye Chen, Zhong-Wen Luo, N. Cui, Xiao-Bing Wang, Lingyi Kong

Journal of Medicinal Chemistry

DOI

2021

Discovery of First-in-Class Dual PARP and EZH2 Inhibitors for Triple-Negative Breast Cancer with Wild-Type BRCA.

Cheng Wang, Lailiang Qu, Shang Li, Fucheng Yin, Limei Ji, Wan Peng, Heng Luo, Dehua Lu, Xingchen Liu, Xinye Chen, Lingyi Kong, Xiaobing Wang

Journal of Medicinal Chemistry

DOI

2021

Synthesis and evaluation of multi-target-directed ligands with BACE-1 inhibitory and Nrf2 agonist activities as potential agents against Alzheimer's disease.

Lailiang Qu, Limei Ji, Cheng Wang, Heng Luo, Shang Li, Wan Peng, Fucheng Yin, Dehua Lu, Xingchen Liu, Ling-Yi Kong, Xiaobing Wang

European journal of medicinal chemistry

DOI

2021

Discovery of PT-65 as a highly potent and selective Proteolysis-targeting chimera degrader of GSK3 for treating Alzheimer's disease.

Lailiang Qu, Shang Li, Limei Ji, Si-Yuan Luo, Ming Ding, Fucheng Yin, Cheng Wang, Heng Luo, Dehua Lu, Xingchen Liu, Wan Peng, Ling-Yi Kong, Xiaobing Wang

European journal of medicinal chemistry

DOI

2020

Development of a Tau-Targeted Drug Delivery System using a Multifunctional Nanoscale Metal-Organic Framework for Alzheimer's Disease Therapy.

Jin-Hua Zhao, Fucheng Yin, Limei Ji, Cheng Wang, Cunjian Shi, Xingchen Liu, Huali Yang, Xiaobing Wang, Ling-Yi Kong

ACS Applied Materials and Interfaces

DOI

2020

Identification and optimization of piperlongumine analogues as potential antioxidant and anti-inflammatory agents via activation of Nrf2.

Limei Ji, Lailiang Qu, Cheng Wang, Wan Peng, Shun-Jie Li, Huali Yang, Heng Luo, Fucheng Yin, Dehua Lu, Xingchen Liu, Ling-Yi Kong, Xiaobing Wang

European journal of medicinal chemistry

DOI

2020

Design and SAR of withangulatin A analogs that act as covalent TrxR inhibitors through Michael addition reaction showing potential in cancer treatment.

Cheng Wang, Shun-Jie Li, Jin-Hua Zhao, Huali Yang, Fucheng Yin, Ming Ding, Jian-Guang Luo, Xiaobing Wang, Ling-Yi Kong

Journal of Medicinal Chemistry

DOI

2020

Chromone and donepezil hybrids as new multipotent cholinesterase and monoamine oxidase inhibitors for the potential treatment of Alzheimer's disease.

Xiaobing Wang, Fucheng Yin, Ming Huang, Neng Jiang, Jin-Shuai Lan, Ling-Yi Kong

RSC Medicinal Chemistry

DOI

2020

Optimization of WZ4003 as NUAK inhibitors against human colorectal cancer.

Huali Yang, Xiaobing Wang, Cheng Wang, Fucheng Yin, Lailiang Qu, Cunjian Shi, Jin-Hua Zhao, Shun-Jie Li, Limei Ji, Wan Peng, Heng Luo, Mao-Sheng Cheng, Ling-Yi Kong

European journal of medicinal chemistry

DOI

2019

A hemicyanine derivative for near-infrared imaging of β-amyloid plaques in Alzheimer's disease.

Huali Yang, Siqiang Fang, Yan-Wei Tang, Cheng Wang, Heng Luo, Lailiang Qu, Jin-Hua Zhao, Cunjian Shi, Fucheng Yin, Xiaobing Wang, Ling-Yi Kong

European journal of medicinal chemistry

DOI

2019

Palladium-Catalyzed meta-C-H Olefination of Arene-Tethered Diols Directed by Well-Designed Pyrimidine-Based Group.

Siqiang Fang, Xiaobing Wang, Fucheng Yin, Pei Cai, Huali Yang, Lingyi Kong

Organic Letters

DOI

精选作品

期刊论文

Discover of a highly effective covalent inhibitor of CDK6 for triple-negative breast cancer treatment.

Cascade synthesis of miltirone derivatives via arylation, decarboxylation, and aromatization for their potential as antitumor agents.

Design and Synthesis of PARP/CDK6 Dual-Target Inhibitors Modulating of Wnt/β-Catenin Signaling Pathway for the Treatment of BRCA Wild-Type TNBC.

Correction to "Discovery of Dual CDK6/BRD4 Inhibitor Inducing Apoptosis and Increasing the Sensitivity of Ferroptosis in Triple-Negative Breast Cancer".

Stereoselective Synthesis of β, γ-Fused Bicyclic γ-Ureasultams via an Intramolecular Mannich and aza-Michael Addition Cascade.

Regioselective Olefination and Arylation of Arene-Tethered Diols Using the Easily Foldable Directing Groups.

Polypharmacological Drug Design Guided by Integrating Phenotypic and Restricted Fragment Docking Strategies.

Discovery of Dual CDK6/BRD4 Inhibitor Inducing Apoptosis and Increasing the Sensitivity of Ferroptosis in Triple-Negative Breast Cancer.

Progress in approved drugs from natural product resources.

Discovery of Covalent MLKL PROTAC Degraders via Optimization of a Theophylline Derivative Ligand for Treating Necroptosis.

Copper(II)/Rhodium(III)‐Catalyzed Three‐Component Sequential Annulation‐Olefination of 2‐Arylquinoxalines

Improving tumor sensitivity by the introduction of an ester chain to triaryl derivatives targeting PD-1/PD-L1.

Two types of coumarins-specific enzymes complete the last missing steps in pyran- and furanocoumarins biosynthesis

Dual target PARP1/EZH2 inhibitors inducing excessive autophagy and producing synthetic lethality for triple-negative breast cancer therapy.

Discovery, Structure, and Mechanism of the (R, S)-Norcoclaurine Synthase for the Chiral Synthesis of Benzylisoquinoline Alkaloids

Oxazole-4-carboxamide/butylated hydroxytoluene hybrids with GSK-3β inhibitory and neuroprotective activities against Alzheimer's disease.

Indirubin derivatives as bifunctional molecules inducing DNA damage and targeting PARP for the treatment of cancer.

Discovery of dual PARP and CDK6 inhibitors for triple-negative breast cancer with wild-type BRCA.

Discovery of Sibiriline derivatives as novel receptor-interacting protein kinase 1 inhibitors.

Design, synthesis and mechanism studies of dual EZH2/BRD4 inhibitors for cancer therapy.

Discovery of precision targeting EZH2 degraders for triple-negative breast cancer.

Histone Deacetylase and Enhancer of Zeste Homologue 2 Dual Inhibitors Presenting a Synergistic Effect for the Treatment of Hematological Malignancies.

Harmine-based dual inhibitors targeting histone deacetylase (HDAC) and DNA as a promising strategy for cancer therapy.

Aryl Halides as Halogenation Reagents in the Bromination and Iodination of Arene-Tethered Diols.

Rhodium(III)‐ Catalyzed Cleavage of C‐C Bond and C‐H Bond Cascaded by Michael Addition for the Conversion of α‐Hydroxy Ketones to Phthalides and Isocoumarins

Rhodium(iii) catalyzed olefination and deuteration of tetrahydrocarbazole

Parthenolide Derivatives as PKM2 Activators Showing Potential in Colorectal Cancer.

Discovery of First-in-Class Dual PARP and EZH2 Inhibitors for Triple-Negative Breast Cancer with Wild-Type BRCA.

Synthesis and evaluation of multi-target-directed ligands with BACE-1 inhibitory and Nrf2 agonist activities as potential agents against Alzheimer's disease.

Discovery of PT-65 as a highly potent and selective Proteolysis-targeting chimera degrader of GSK3 for treating Alzheimer's disease.

Development of a Tau-Targeted Drug Delivery System using a Multifunctional Nanoscale Metal-Organic Framework for Alzheimer's Disease Therapy.

Identification and optimization of piperlongumine analogues as potential antioxidant and anti-inflammatory agents via activation of Nrf2.

Design and SAR of withangulatin A analogs that act as covalent TrxR inhibitors through Michael addition reaction showing potential in cancer treatment.

Chromone and donepezil hybrids as new multipotent cholinesterase and monoamine oxidase inhibitors for the potential treatment of Alzheimer's disease.

Optimization of WZ4003 as NUAK inhibitors against human colorectal cancer.

A hemicyanine derivative for near-infrared imaging of β-amyloid plaques in Alzheimer's disease.

Palladium-Catalyzed meta-C-H Olefination of Arene-Tethered Diols Directed by Well-Designed Pyrimidine-Based Group.

会议论文

Investigation of lithium insertion in anode material NiSi 2 for lithium-ion batteries

Thermodynamic assessment of Zn-Fe-Nb ternary system

Experimental Investigation and Thermodynamic Description of the Li-Si-Ni Ternary System

Partial Liquidus Projection of the B-Fe-Mo Ternary System

The zinc rich corner of the Zn-Al-Co-Fe quaternary system at 450℃